Clinical Trial

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Systemic lupus erythematosus (SLE).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-09-03; most recent amendment 2026-03-06.
Status change: Not Yet Recruiting → Recruiting 2024-11-07
Trial Details
NCT Number NCT06585514
Lead Sponsor Beijing GoBroad Hospital
Conditions Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Enrollment 18 participants
Start Date 2024-10-17
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-10